Aminolevulinic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Afatinib
Tyrosine Kinase Inhibitor · Antineoplastic
Tyrosine Kinase InhibitorAntineoplasticATC null
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
7 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 8 →
- Aminolevulinic AcidSevereDatabaseDDInter
- LeflunomideSevereDatabaseDDInter
- LomitapideSevereDatabaseDDInter
- MipomersenSevereDatabaseDDInter
Mechanism
Afatinib is a protein kinase inhibitor that specifically inhibits the kinase domains of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. This inhibition leads to the suppression of downstream ErbB signaling pathways.
Indications
Treatment of locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations, in patients who have not previously been treated with EGFR tyrosine kinase inhibitorlung NSCLC (EGFR deletion of exon 19 or L858R mutation)first-line treatment of patients with metastatic NSCLC with EGFR mutationsmetastatic squamous NSCLC that has progressed subsequent to platinum-based chemotherapy
Dosing
- Adult
- Oral: 40 mg once daily; increased if tolerated to up to 50 mg once daily, dose increase may be considered after 3 weeks at initial dose.
- Renal adjustment
- In patients with severe renal impairment, a dose reduction is recommended.
- Max dose
- 50 mg once daily
Pharmacokinetics
Half-life
37 h (after repeat dosing)
Contraindications
- Cardiac risk factors
- Conditions which may affect left ventricular ejection fraction
- Diarrhoea
- Exposure to sun (protect skin from exposure to sun)
- History of keratitis
- New pulmonary symptoms (including dyspnoea, cough, fever)
- Severe dry eyes
- Signs and symptoms of keratitis
- Signs and symptoms of skin reaction
Side effects
Common
DiarrheaSkin rashAnorexiaDry eyesacneiform dermatitisstomatitishand-foot skin reactionsnail changes
Serious
- Interstitial lung disease
- Hepatotoxicity
- Keratitis
- Stevens-Johnson syndrome
- New pulmonary symptoms (dyspnoea, cough, fever)
- liver function abnormalities
- left ventricular dysfunction
- gastrointestinal perforation (0.2% of patients)
Pregnancy & lactation
Pregnancy
X
Drug interactions
Leflunomide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Lomitapide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Mipomersen
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ozanimod
Severe
Database
Drug interaction classified as: others
Source: DDInter
Pexidartinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Teriflunomide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Pgp Modulating Drugs
Moderate
Textbook
Altered afatinib concentrations.
Source: G&G 14e · p1385
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Tyrosine Kinase Inhibitor drugs
Ask House about Afatinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team